Detection of glioblastoma response to temozolomide combined with bevacizumab based on μmRI and μpET imaging reveals [18F]- fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

Neuro-Oncology

Volumn 15, Issue 1, 2013, Pages 41-56

  Corroyer Dulmont, Aurélien ^a,b,c   Pérès, Elodie A ^a,b,c   Petit, Edwige ^a,b,c   Guillamo, Jean Sébastien ^a,b,c,d   Varoqueaux, Nathalie ^e   Roussel, Simon ^a,b,c   Toutain, Jérôme ^a,b,c   Divoux, Didier ^a,b,c   MacKenzie, Eric T ^a,b,c   Delamare, Jérôme ^a,b,c   Ibazizène, Méziane ^a,b,c   Lecocq, Myriam ^a,b,c   Jacobs, Andréas H ^f   Barré, Louisa ^a,b,c   Bernaudin, Myriam ^a,b,c   Valable, Samuel ^a,b,c  

^a CNRS   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c DIF   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Roche SAS   (France)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

anti angiogenic; chemotherapy; FLT PET; glioma; MRI

Indexed keywords

BEVACIZUMAB; FLUORO LEVO THYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VOLUME; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; GLIOBLASTOMA; IMAGE PROCESSING; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RAT; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; DACARBAZINE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871990261     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos260     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Desjardins A, Friedman HS. Neuro-oncology: glioblastoma-community adjusts to new standard of care. Nat Rev Neurol. 2012;8:244-246.
3. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610-622. (Pubitemid 47093931)
4. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455-468.
5. Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76:87-93.
6. Mathieu V, De Nè ve N, Le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10:1383-1392.
7. Jakobsen JN, Hasselbalch B, Stockhausen M, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011;12:825-833.
8. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
9. Pé rez-Larraya JG, Lahutte M, Petrirena G, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol. 2012;14:665-673.
10. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009;9:241-246.
11. Pope WB, Young JR, Ellingson BM. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep. 2011;11:336-344.
12. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
13. Yamasaki F, Sugiyama K, Ohtaki M, et al. Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol. 2010;73:532-537.
14. Lemasson B, Christen T, Tizon X, et al. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR Biomed. 2011;24:473-482.
15. Galbá n CJ, Bhojani MS, Lee KC, et al. Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucosepositron emission tomography imaging biomarkers. Clin Cancer Res. 2010;16:1542-1552.
16. Valable S, Lemasson B, Farion R, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed. 2008;21:1043-1056.
17. Lemasson B, Valable S, Farion R, Krainik A, Rémy C, Barbier EL. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. 2012; in press.
18. Wester H. Nuclear imaging probes: from bench to bedside. Clin Cancer Res. 2007;13:3470-3481. (Pubitemid 46955106)
19. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958. (Pubitemid 46657440)
20. Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L- tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856-864.
21. Derlon JM, Chapon F, Noë l MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778-787. (Pubitemid 30456760)
22. Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2011;118: 1302-1312.
23. Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-378.
24. Valable S, Eddi D, Constans JM, et al. MRI assessment of hemodynamic effects of an angiopoietin-2 overexpression on a brain tumor model. Neuro Oncol. 2009;11:488-502.
25. von Baumgarten LD, Brucker D, Tirniceru AL, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17:6192-205.
26. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29:853-860.
27. Valable S, Petit E, Roussel S, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38:781-793.
28. Horsthuis K, Nederveen AJ, de Feiter M, Lavini C, Stokkers PCF, Stoker J. Mapping of T1-values and gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn's disease: a feasibility study. J Magn Reson Imaging. 2009;29:488-493.
29. Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32:882-889.
30. Radaelli E, Ceruti R, Patton V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009;24:879-891.
31. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17:4119-4124.
32. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37:36-42.
33. Carnaghi C, Sclafani F, Basilico V, Doherty M. Response assessment in oncology: limitations of anatomic response criteria in the era of tailored treatments. Q J Nucl Med Mol Imaging. 2011;55:589-602.
34. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 2012;18:40-44.
35. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
36. Jensen MM, Erichsen KD, Bjö rkling F, et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010;5:e12965.
37. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3′-deoxy-3′- 18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29-36.
38. Spence AM, Muzi M, Link JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F] fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009;11:343-355.
39. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049-2055. (Pubitemid 351551115)
40. Rueger MA, Backes H, Walberer M, et al. Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography. J Neurosci. 2010;30:6454-6460.
41. Zhang CC, Yan Z, LiW, et al. [18F]FLT-PET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res. 2011;18:1303-1312.
42. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25: 4714-4721. (Pubitemid 350086472)
43. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108: 3749-3754.